{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-26-000006","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.883285+00:00","generated_at":"2026-05-15T19:27:12.381475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint","bullets":["Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.","Type C FDA meeting scheduled mid-April 2026 to review EFZO-FIT results and determine path forward for efzofitimod in pulmonary sarcoidosis.","Phase 2 EFZO-CONNECT in SSc-ILD on track to complete enrollment in first half 2026; interim data reported Q2 2025.","Year-end 2025 cash position $80.9 million; R&D expenses $60.2 million, G&A $17.6 million for the year."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-26-000006","json":"https://secwatch.observer/filing/0001339970-26-000006.json","markdown":"https://secwatch.observer/filing/0001339970-26-000006.md","text":"https://secwatch.observer/filing/0001339970-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/0001339970-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/atyr-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:27:12.381475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3dbc628f43d4ff68600a4e6f29b5dfb9e624db12","claim":"aTYR PHARMA INC reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/0001339970-26-000006-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}